Anacardic Acid

Anacardic Acid

SCHEMBL627981

CCCCCCCCCCCCCCCc1cccc(O)c1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 7/20 1.00
MCL1 Q07820 7/20 1.00
BCL2L1 Q07817 6/20 1.00
BAK1 Q16611 6/20 1.00
KAT8 Q9H7Z6 3/20 1.00
PPARA Q07869 3/20 1.00
SAE1 Q9UBE0 2/20 1.00
EP300 Q09472 2/20 1.00
KAT5 Q92993 2/20 1.00
PPARG P37231 2/20 1.00
KAT2A Q92830 1/20 1.00
KAT2B Q92831 1/20 1.00
F7 P08709 3/20 0.84
F3 P13726 3/20 0.84
MMP2 P08253 2/20 0.84
KDM4E B2RXH2 1/20 0.84
MAPT P10636 1/20 0.84
ALOX15 P16050 1/20 0.84
ECE1 P42892 1/20 0.84
SGMS1 Q86VZ5 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2558603 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
Ginkgolic Acid 13:0 SCHEMBL20298323 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5378937 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL10877233 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5379149 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL4248799 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5378991 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL16237264 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL2126888 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8
Anacardic Acid SCHEMBL29408556 1.00 BID (1.00) BIDMCL1BCL2L1BAK1KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250216402-A1 BIOMARKERS FOR SEVERITY OF ISCHEMIC STROKE AND USE THEREOF ZHEJIANG CHINESE MEDICAL UNIVERSITY (CN) 2025-07-03 US claimed
CN-120005443-A Low-VOC-emission special printing ink for children's painting and preparation method and application thereof 浙江华旭实业有限公司 2025-05-16 CN claimed
WO-2025030135-A2 METHODS FOR TREATING AND AMELIORATING ANGINA, MYOCARDIAL INFARCTION, REPERFUSION INJURY, HEART ARRHYTHMIAS AND CONGESTIVE HEART FAILURE (CHF) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-06 WO claimed
CN-117929747-A Biomarker for severity of ischemic cerebral apoplexy and application thereof 浙江中医药大学 2024-04-26 CN claimed
US-20170095436-A1 METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY THE JOHNS HOPKINS UNIVERSITY (US) 2017-04-06 US claimed
WO-2015184260-A2 METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY THE JOHNS HOPKINS UNIVERSITY (US) 2015-12-03 WO claimed
US-7196214-B2 Process for arylamine production XEROX CORPORATION (US) 2007-03-27 US claimed
US-20060111582-A1 Process for arylamine production XEROX CORPORATION (US) 2006-05-25 US claimed
US-5240962-A Antiobesity and fat-reducing agents TAKASAGO INSTITUTE FOR INTERDISCIPLINARY SCIENCE, INC. (US) 1993-08-31 US claimed
JP-5170645-A None JP disclosed
JP-2255609-A None JP disclosed
CN-122075461-A Application of anacardic acid in preparation of core protease I7L activity inhibitor and anti-orthopoxvirus infection medicine 2026-05-26 CN disclosed
US-12552959-B2 Aqueous coating composition for corrosion protection ALLNEX AUSTRIA GMBH (AT) 2026-02-17 US disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US disclosed
WO-2003062201-A1 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) 2003-07-31 WO disclosed
US-6117431-A Method for obtaining an extract from ginkgo biloba leaves PHARMLINE INC. (US) 2000-09-12 US disclosed
US-5240962-A Antiobesity and fat-reducing agents TAKASAGO INSTITUTE FOR INTERDISCIPLINARY SCIENCE, INC. (US) 1993-08-31 US disclosed
JP-H05170645-A INHIBITOR OF CARBOHYDRATE-HYDROLYZING ENZYME IN INTESTINE TAKASAGO INST FOR INTERDISCIPLINARY SCI INC 1993-07-09 JP disclosed
US-5202355-A Administering for diabetic neuropathy TAKASAGO INSTITUTE FOR INTERDISCIPLINARY SCIENCE INC. (US) 1993-04-13 US disclosed
JP-H02255609-A ANTIMICROBIAL AGENT COMPOSITION FOR ORAL CAVITY SUNSTAR INC 1990-10-16 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552959-B2 Aqueous coating composition for corrosion protection ADH1A, ADH1C, TET1 BID 4218/4885MCL1 1367/4885BCL2L1 4641/4885
US-20060111582-A1 Process for arylamine production AOC2, UFM1, TYR BID 3728/4885MCL1 3212/4885BCL2L1 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.